<DOC>
	<DOC>NCT00033111</DOC>
	<brief_summary>The purpose of this study is to assess cabergoline for the Treatment of Cocaine Dependence</brief_summary>
	<brief_title>A Study of Cabergoline for the Treatment of Cocaine Dependence - 1</brief_title>
	<detailed_description>To assess the efficacy and safety of cabergoline in reducing cocaine use in subjects with cocaine dependence. This is a DB, placebo-controlled, parallel group design study where subjects will receive either .5mg cabergoline or placebo for 12 weeks with a 4 week follow-up.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>Must have a DSM4 criteria for cocaine dependence; be seeking treatment for cocaine dependence; have the ability to understand and provide written informed consent; females of childbearing potential using proper method of birth control. Additional criteria available during screening at the site.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>